Trial Profile
A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Azacitidine
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Roche
- 15 Aug 2019 Status changed from suspended to completed.
- 04 Dec 2018 Results (Data cut off Jan 2018, n=42) assessing initial Safety and Efficacy Analysis, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 15 Feb 2018 Status changed from recruiting to suspended.